ABT
Abbott Laboratories
Health Care · Health Care Equipment · US
$91.07
Data: 2026-05-15
✓ ETHICAL PASS

MODERATE MOAT
HIGH
Data Confidence: 100.0%
Key Metrics

How this company measures up on the fundamentals that matter

Market Cap
$146.9B
Total market value of the company
23.63
Premium valuation
13.91
Based on estimated future earnings — lower means cheaper
Rev Growth
+7.8%
Year-over-year revenue change
Profit Margin
13.9%
How much profit the company keeps from each dollar of revenue
12.3%
Return on equity — how efficiently it uses shareholder money
Analyst Target
$118.64
+30% from current price — median analyst estimate
Recommendation
BUY
Consensus view from 25 analysts covering this stock
About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.

https://www.abbott.com

Country: United States Employees: 122,000 Industry: Medical Devices
Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity
PASS
Core business does not involve prohibited activities
Debt Ratio
16.0% PASS
Debt must be below 33% of total assets
Cash Ratio
0.7% PASS
Interest-bearing cash below 33% of assets
Receivables
19.0% PASS
Receivables below 49% of assets
Revenue Purity
0.7% PASS
Non-compliant revenue below 5% — any excess requires purification
Valuation
$72.77
What our model estimates this business is worth per share
-25.1%
Trading above fair value — no margin of safety
Rating
OPPORTUNITY
Overall assessment combining ethics, valuation, and quality
96.5th
Ranks in the top 4% of our 13,571 screened universe
Ethical Score
87.2
Valuation Score
71.5
Quality Score
60.3
Combined
72.1

Trading at $84, 16% above fair value of $73. Moderate competitive position. Passes all ethical screens. Ranks better than 96% of screened stocks.

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

DISTRIBUTION
Smart money appears to be selling into strength — caution
-0.160
Returns do not compensate for the risk — negative edge
-0.0168
No positive edge detected — the data suggests staying out
-0.151
Drawdown risk outweighs the returns — higher risk profile
Annual Return
-6.0%
Historical annualised return based on price data
-39.6%
Largest peak-to-trough decline — the worst it has been
BULL
Statistical model sees bullish momentum
Days in State
24
How long the current regime has persisted — longer means more stable
Market Data

Trading characteristics and market positioning

0.65
Less volatile than the market — more defensive
52W High
$139.06
35% below the year high
52W Low
$81.97
11% above the year low
Avg Volume
12,005,761
Average daily shares traded — higher means easier to buy and sell
1.8
Days it would take all short sellers to cover — higher means more crowded
Short % Float
1.5%
Low short interest — limited bearish positioning
3.0%
Annual dividend as a percentage of the share price
$3.57
Earnings per share over the last 12 months
Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

0.65
Moderate leverage — manageable
1.39
Adequate but worth monitoring
Quick Ratio
0.84
Like current ratio but excludes inventory — stricter test
Gross Margin
56.5%
Revenue left after cost of goods — higher means pricing power
Operating Margin
13.5%
Profit from core operations before interest and tax
$6.3B
Positive — the business generates more cash than it spends
Revenue (TTM)
$45.1B
Total revenue over the last 12 months
Net Income
$6.3B
Profitable — the bottom line is positive
Analyst Coverage
Analysts
25
Target High
$143.00
Target Median
$118.64
Target Low
$92.00
Recent Insider Activity

SEC Form 4 filings — what company insiders are buying and selling

45
NEUTRAL
Mixed insider activity. 0 purchases and 0 sales in the last 90 days — no clear directional signal. Political selling noted.
Date Insider Title Type Shares Value
2026-04-27 STARKS DANIEL J Director 10,000 $926,537
2026-04-24 STRATTON JOHN G. Director 2,286
2026-04-24 CONROY KEVIN T Director 2,286
2026-04-24 MCKINSTRY NANCY Director 2,286
2026-04-24 KUMBIER MICHELLE A Director 2,286
2026-04-24 BABINEAUX CLAIRE FONTENOT Director 2,286
2026-04-24 MCDEW DARREN W Director 2,286
2026-04-24 GONZALEZ PATRICIA PAOLA Director 2,286
2026-04-24 AHUJA NITA M.D. Director 2,286
2026-04-24 O GRADY MICHAEL G Director 2,286
Source: SEC Form 4 filings via public data. View all insider activity at
Insider Intelligence
Political Trading Activity

Congressional trading disclosures involving this instrument

Date Politician Party Type Amount
27 May2026 Josh Gottheimer Democrat sell 1K–15K
2026-04-13 Ro Khanna Democrat Sale 1K–15K
Source: Congressional disclosure filings. View all political trades at
Insider Intelligence
Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-15

Discover More
Alpha Insights Market Intelligence Titan Watch Ethical Screener Insider Intelligence Track Record Ethical Finance Zakat Calculator Iran Oil Tracker Foundry (292 articles) Indicators Join Free →

Get our weekly market brief free.